TOVEDESO

This brand name is authorized in Croatia, Germany, Spain.

Active ingredients

The drug TOVEDESO contains one active pharmaceutical ingredient (API):

1	Desfesoterodine UNII 90Y3ELK3FB - DESFESOTERODINE SUCCINATE
	Desfesoterodine is a competitive, specific muscarinic receptor antagonist. It is the primary active metabolite of fesoterodine, and regarded as main active pharmacological principle of fesoterodine; fesoterodine is considered as prodrug of desfesoterodine. The affinity of desfesoterodine for the muscarinic receptors is 2 orders of magnitude greater than that of fesoterodine.
	Read more about Desfesoterodine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TOVEDESO Prolonged-release tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G04BD13		G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics
Discover more medicines within G04BD13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	12447982, 12447999, 12448013, 12448042, 13754829, 13754835
ES	Centro de información online de medicamentos de la AEMPS	82434, 82435
HR	Agencija za lijekove i medicinske proizvode	HR-H-219578792, HR-H-862475317